Citizen Petition calls on US FDA to review regulation of homeopathic drugs

18 September 2011

The Center for Inquiry (CFI) and its affiliate, the Committee for Skeptical Inquiry (CSI), both non-profit educational organizations in the USA, have filed a Citizen Petition with the Food and Drug Administration requesting that the FDA initiate rulemaking that would require over-the-counter homeopathic drugs to meet the same standards of effectiveness as non-homeopathic drugs. Although the FDA has the authority to require homeopathic drugs to undergo testing for effectiveness, it has to date declined to do so.

Homeopathic drugs were previously marketed on a relatively small scale, but their sales
have been burgeoning in the last couple decades. In 2009, consumer sales of homeopathic treatments in the USA reached $870 million, it was noted.

Homeopathic drugs are controversial because most scientists and physicians maintain there is no reliable scientific evidence to support the therapeutic claims made for these drugs. Homeopathic remedies were first developed in the late 1700s, before the advent of modern medicine. Homeopathic drugs are produced by taking a substance that is believed to cause disease symptoms and then diluting the substance repeatedly until, according to accepted laws of chemistry, there are no molecules left of the original substance. But homeopaths insist that by virtue of some scientifically inexplicable process, their drugs possess therapeutic value.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical